Skip to main content Accessibility help
×
Home

Antipsychotics: is it time to introduce patient choice?

  • Anthony P. Morrison (a1), Paul Hutton (a2), David Shiers (a3) and Douglas Turkington (a4)

Summary

Evidence regarding overestimation of the efficacy of antipsychotics and underestimation of their toxicity, as well as emerging data regarding alternative treatment options, suggests it may be time to introduce patient choice and reconsider whether everyone who meets the criteria for a schizophrenia spectrum diagnosis requires antipsychotics in order to recover.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Antipsychotics: is it time to introduce patient choice?
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Antipsychotics: is it time to introduce patient choice?
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Antipsychotics: is it time to introduce patient choice?
      Available formats
      ×

Copyright

Corresponding author

Anthony P. Morrison, School of Psychological Sciences, University of Manchester, Manchester M13 9PL, UK. Email: tony.morrison@manchester.ac.uk

Footnotes

Hide All

Declaration of interest

A.P.M. and D.S. are both members of two National Institute for Health and Clinical Excellence guideline development groups: Psychosis and Schizophrenia in Children and Young People, and Psychosis and Schizophrenia in Adults (partial update).

Footnotes

References

Hide All
1 Leucht, S, Arbter, D, Engel, RR, Kissling, W, Davis, JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009; 14: 429–47.
2 Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006; 31: 2318–25.
3 Lepping, P, Sambhi, RS, Whittington, R, Lane, S, Poole, R. Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 2011; 198: 341–5.
4 Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 3141.
5 Artaloytia, JF, Arango, C, Lahti, A, Sanz, J, Pascual, A, Cubero, P, et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 2006; 163: 488–93.
6 Moncrieff, J, Leo, J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med 2010; 40: 1409–22.
7 Ray, WA, Chung, CP, Murray, KT, Hall, K, Stein, CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–35.
8 Weinmann, S, Read, J, Aderhold, V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009; 113: 111.
9 Foley, DL, Morley, KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011; 68: 609–16.
10 Álvarez-Jiménez, M, Hetrick, SE, González-Blanch, C, Gleeson, JF, McGorry, PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008; 193: 101–7.
11 Marques, TR, Arenovich, T, Agid, O, Sajeev, G, Muthen, B, Chen, L, et al. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med 2011; 41: 1481–8.
12 Perkins, D, Lieberman, J, Gu, H, Tohen, M, McEvoy, J, Green, A, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004; 185: 1824.
13 Harrow, M, Jobe, TH, Faull, RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. In Psychol Med 2012; Feb 17 (Epub ahead of print).
14 Morrison, AP, Hutton, P, Wardle, M, Spencer, H, Barratt, S, Brabban, A, et al. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychol Med 2012; 42: 1049–56.
15 Day, JC, Bentall, RP, Roberts, C, Randall, F, Rogers, A, Cattell, D, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005; 62: 717–24.

Antipsychotics: is it time to introduce patient choice?

  • Anthony P. Morrison (a1), Paul Hutton (a2), David Shiers (a3) and Douglas Turkington (a4)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Antipsychotics: is it time to introduce patient choice?

  • Anthony P. Morrison (a1), Paul Hutton (a2), David Shiers (a3) and Douglas Turkington (a4)
Submit a response

eLetters

We encountered an error trying to retrieve eLetters for this article. Please try again or contact Customer Services

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *